Eli Lilly and Company’s LLY shares have risen 4.3% since it reported fourth-quarter results on Feb. 6. Lilly’s fourth-quarter ...

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

If the FDA follows an advisory committee’s vote, it can potentially be a transformative step in the delivery of mental health ...

The case for GLP-1 drugs like Ozempic possibly causing blindness is building. A new paper out this week describes several ...

People taking weight-loss drugs say they are losing their sight. Science is trying to figure out why - There’s no direct link ...

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...

Next-generation obesity drugs will work differently from Ozempic and Wegovy — aiming to deliver greater weight loss with ...

Jeffrey Stark, MD, vice president and head of medical immunology at UCB, discusses tailored dosing of bimekizumab-bkzx ...

Hims & Hers is under scrutiny for promoting compounded weight-loss drugs in a Super Bowl ad without clear FDA approval or ...

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...

Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.